Literature DB >> 20596642

Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma.

Daisuke Nobuoka1, Yuichiro Kato, Naoto Gotohda, Shinichiro Takahashi, Toshio Nakagohri, Masaru Konishi, Taira Kinoshita, Tetsuya Nakatsura.   

Abstract

We evaluated the clinical value of perioperative alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) levels in predicting recurrence of hepatocellular carcinoma (HCC) after curative resection, with a focus on the time course as surveillance tools. A total of 165 consecutive HCC patients who had undergone curative hepatectomy at our institution from 2005 to 2007 and whose serum AFP and DCP had been measured before and after hepatectomy were included in this study. The minimum postoperative levels within a 4-month period were used for analysis. Among the patients with a positive level of AFP before operation, the number of patients whose AFP level did not change from positive to negative after operation in the group with recurrence exceeded that in the group without recurrence (48/60, 80.0% vs. 4/23, 17.4%), and the difference was significant (P<0.001). Minimum postoperative AFP level was found to be a significant independent risk factor for recurrence by multivariate analysis (P<0.001). There was no statistically significant correlation between AFP level and grade of hepatitis activity (P=0.599). Postoperative AFP level is a useful tool for predicting recurrence after curative hepatectomy. A positive level of AFP after operation might suggest a site of residual viable cancer. The need for effective adjuvant therapy and close follow-up is suggested in patients with a positive postoperative AFP level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596642     DOI: 10.3892/or_00000888

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  The postresection alpha-fetoprotein in cirrhotic patients with hepatocellular carcinoma. An independent predictor of outcome.

Authors:  Marc-Antoine Allard; Antonio Sa Cunha; Aldrick Ruiz; Eric Vibert; Mylène Sebagh; Denis Castaing; René Adam
Journal:  J Gastrointest Surg       Date:  2014-01-09       Impact factor: 3.452

2.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

Review 3.  Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus.

Authors:  Tianfu Wen; Chen Jin; Antonio Facciorusso; Matteo Donadon; Ho-Seong Han; Yilei Mao; Chaoliu Dai; Shuqun Cheng; Bixiang Zhang; Baogang Peng; Shunda Du; Changjun Jia; Feng Xu; Jie Shi; Juxian Sun; Peng Zhu; Satoshi Nara; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

4.  A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.

Authors:  Cheng Xu; Zhehui Yan; Liang Zhou; Yuming Wang
Journal:  J Cancer Res Clin Oncol       Date:  2013-06-07       Impact factor: 4.553

Review 5.  Biomarkers for the early diagnosis of hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Keigo Saito; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

6.  Liver transplantation versus surgical resection for HCC meeting the Milan criteria: A propensity score analysis.

Authors:  Jun-Yi Shen; Chuan Li; Tian-Fu Wen; Lv-Nan Yan; Bo Li; Wen-Tao Wang; Jia-Yin Yang; Ming-Qing Xu; Tholakkara Nazar Highness
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

7.  Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.

Authors:  Yuri Jeong; Sang Min Yoon; Seungbong Han; Ju Hyun Shim; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; So Yeon Kim; Jin-hong Park; Sang-wook Lee; Seung Do Ahn; Eun Kyung Choi; Jong Hoon Kim
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

8.  Changes in highly sensitive alpha-fetoprotein for the prediction of the outcome in patients with hepatocellular carcinoma after hepatectomy.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Takanori Ito; Atsuyuki Maeda; Yuji Kaneoka; Chiaki Kagebayashi; Shinji Satomura
Journal:  Cancer Med       Date:  2014-03-03       Impact factor: 4.452

9.  MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection.

Authors:  Wei Liu; Na Wang; Min Lu; Xiao-Juan Du; Bao-Cai Xing
Journal:  Mol Med Rep       Date:  2016-06-15       Impact factor: 2.952

10.  Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.

Authors:  Tae Yoo; Kwang-Woong Lee; Nam-Joon Yi; Young Rok Choi; Hyeyoung Kim; Suk-Won Suh; Jae Hong Jeong; Jeong-Moo Lee; Kyung-Suk Suh
Journal:  J Korean Med Sci       Date:  2016-04-20       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.